Skip to content

Gregory Jones

2 papers in the library · publishing 2023-2026

Papers

Sort Most recent Most cited

Modulation of early non-rapid eye movement slow wave activity by ketamine in treatment-resistant depression.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology June 16, 2026 Nadia S. Hejazi, Mina Kheirkhah, Brady A. Riedner et al.

Slow-wave activity (SWA), a key indicator of sleep homeostasis, is often diminished in individuals with treatment-resistant depression (TRD). Ketamine, a rapid-acting antidepressant, increases SWA during the first period of non-rapid eye movement (NREM1) sleep. However, research into how ketamine affects sleep and its connection to treatment outcomes in TRD has been limited by small sample...

Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression.

Pharmaceuticals (Basel, Switzerland) November 7, 2023 Courtney M Vecera, Alan C. Courtes, Gregory Jones et al.

Treatment-resistant depression (TRD) is a term used to describe a particular type of major depressive disorder (MDD). There is no consensus about what defines TRD, with various studies describing between 1 and 4 failures of antidepressant therapies, with or without electroconvulsive therapy (ECT). That is why TRD is such a growing concern among clinicians and researchers, and it explains the...